普昂医疗实控人无技术研发背景，却称核心专利唯一发明人？

Core Viewpoint - Puang Medical, a high-tech enterprise focusing on diabetes care and minimally invasive medical devices, is preparing for its market debut amid concerns regarding its core technology sources and executive compliance issues. Group 1: Company Overview - Puang Medical was established in 2013 and has focused on technological innovation and product iteration in the medical device sector, particularly in diabetes care, general drug delivery, and minimally invasive products [1]. - The company has developed patented products such as insulin pen needles, blood collection needles, and syringes, which have gained market recognition due to their differentiated advantages [1]. - The core technology of micro-pain injection is a key competitive advantage, enhancing patient experience by reducing discomfort and operational risks associated with traditional injection devices [1]. Group 2: Technology and Compliance Concerns - The core invention patent for the micro-pain injection technology was applied for by the company's actual controller, Mao Liuying, in October 2013, raising questions about the legitimacy of the technology source as Mao has an accounting background and no disclosed experience in technology research and development [2]. - Concerns have also been raised regarding the compliance of executives, particularly the company's director and R&D director, Lu Yan, who was involved in patent applications while still employed at another medical technology company, leading to questions about potential conflicts of interest [3]. Group 3: Financial Performance and Pricing Strategy - In 2022, the sales price of insulin pen needles was 0.22 yuan per unit, significantly higher than the 0.15 yuan per unit of a competitor, Beipu Medical, which has a gross margin of 62.15%, compared to Puang Medical's 48.28% [4]. - Sales revenue for insulin pen needles in 2022 was 92.96 million yuan, a 62.05% increase from 2021, with sales volume reaching 60.16 million units, reflecting a 67.83% increase [7]. - The gross margin for insulin pen needles decreased from 68.29% in 2021 to 62.15% in 2022, indicating a decline in profitability despite increased sales [8].